menu search

Crypto news: proshares etf shines as vaneck’s etf filing sparks investor interest

ProShares Bitcoin Strategy ETF attracts substantial investor interest, indicating an audience for various BTC exposure methods, including spot ETFs. T...

October 29, 2023, 5:37 am

Bitcoin-friendly el salvador can become the ‘singapore of the americas’: vaneck advisor

Vaneck strategy advisor Gabor Gurbacs says Bitcoin-friendly El Salvador could become the “Singapore o...

October 29, 2023, 4:14 am

Pph: glp-1 companies and large-cap value pharma make for a compelling portfolio

Eli Lilly is a mega-cap stock in the Health Care sector that has performed well in 2023, and it's the top holding in the Va...

October 29, 2023, 2:02 am

Clos gain amid surge in yields

CLOs outperformed investment-grade and high yield bonds in September as fixed-rate debt continues to face headwinds in rising Treasury yields. The Va<...

October 28, 2023, 11:15 am

Emlc: avoid as dollar strength persists

Vaneck J.P. Morgan EM Local Currency Bond ETF is a difficult buy due to the poor performance of emergin...

October 27, 2023, 4:39 pm

Etf of the week: vaneck morningstar wide moat etf (moat)

VettaFi's vice chairman Tom Lydon discussed the ETF of the Week: Vaneck Morningstar Wide Moat ETF (MOAT...

October 26, 2023, 3:07 pm

Gold miners junior (gdxj) should at least see 3 waves rally

The Vaneck Vectors Junior Gold Miners ETF (GDXJ) is an exchange-traded fund that provides exposure to t...

October 25, 2023, 6:00 pm

Vnm: a concentrated frontier-markets fund, low peg, weakening momentum

Frontier Markets, including the Vaneck Vietnam ETF, have underperformed the S&P 500 over the past decad...

October 25, 2023, 12:45 pm

Angle technolgy could help provide a more targeted approach to head and neck cancer

ANGLE plc, a leading company in liquid biopsy technology, has unveiled promising research findings that could help transform the treatment of head and...

October 25, 2023, 2:53 am

Slx: why i am not a buyer

The Vaneck Steel ETF is the closest thing to a pure-play steel ETF currently available. SLX carries a r...

October 24, 2023, 4:31 pm

Lisata therapeutics announces first patient treated in the cholangiocarcinoma cohort of the bolster trial of lsta1, a novel tumor-targeting and penetrating peptide

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-car...

October 24, 2023, 12:00 pm

Nlr: blow-off top in play, eyeing a pullback to support into year end

Uranium and nuclear energy stocks have performed relatively well compared to traditional utilities stocks. Governments around the world may reconsider...

October 24, 2023, 8:04 am

Smh: i prefer individual semiconductor holdings

Vaneck Semiconductor ETF (SMH) has outperformed peer ETFs due to its overweight holding in NVIDIA (NVDA...

October 23, 2023, 11:21 am

Should you invest in the vaneck agribusiness etf (moo)?

Launched on 08/31/2007, the Vaneck Agribusiness ETF (MOO) is a passively managed exchange traded fund d...

October 23, 2023, 7:31 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am

Hookipa pharma presents additional preliminary phase 2 data on hb-200 in combination with pembrolizumab as first-line treatment in patients with hpv16+ head and neck cancers at european society for me

42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and ...

October 22, 2023, 10:01 am


Search within

Pages Search Results: